Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 14

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 1
Chunk 14
---
 expenses(c)(3,053)(4,043)(4,824)(250)(12,170)Operating profit$1,324 $184 $1,937 $(257)$3,188 For the Nine-Month Period Ended September 27, 2024:Sales$4,890 $5,297 $7,150 $— $17,337 Less:Depreciation(113)(123)(292)(6)(534)Amortization of intangible assets(650)(428)(145)— (1,223)Impairments(b)— (222)— — (222)Other segment expenses(c)(2,950)(4,021)(4,712)(237)(11,920)Operating profit (loss)$1,177 $503 $2,001 $(243)$3,438 (a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance.(b) For information on the impairments, refer to Note 8. (c) Other segment expenses for each reportable segment include cost of sales, selling, general and administrative (“SG&A”) expenses and research and development (“R&D”) expenses, excluding in each case depreciation, amortization of intangible assets and impairments.  Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses. The following table presents identifiable assets as of September 26, 2025 and December 31, 2024 ($ in millions):September 26, 2025December 31, 2024Identifiable assets:Biotechnology$37,296 $34,605 Life Sciences23,179 23,211 Diagnostics14,653 14,204 Other4,769 5,522 Total$79,897 $77,542 The following table presents capital expenditures for the three and nine-month periods ended September 26, 2025 and September 27, 2024 ($ in millions):Three-Month Period EndedNine-Month Period EndedSeptember 26, 2025September 27, 2024September 26, 2025September 27, 2024Capital expenditures:Biotechnology$94 $117 $255 $330 Life Sciences40 52 129 162 Diagnostics157 129 397 382 Other1 — 4 2 Total$292